Table 1.

Summary of in vivo results using the three different recombinant ASFV.

		Pre-challenge					Post-challenge
		Dosea	Clinical signs		Viremia			Clinical signs		Viremia
Recombinant ASFV	Group		>40.5°C	Signsb	# pigs	TCID50/mL	Protectionc	>40.5°C	Signs	# pigs	HAD50/mLd
GΔKE_CmutQ96R	K	104	2/6	0/6	6/6	100.75-6.25e	100.0%	0/6	0/6	2/6	100.75f
GΔKE_CmutQ96R/K108D	O	104	2/6	0/6	5/6	100.75-3.75	83.3%	1/6	6/6	2/6	101.75-4.00
GΔDKE_CmutQ96R/K108D	N, S	104	0/12	1/12	6/12	100.75-3.25	83.3%	5/12	3/12	7/12	100.75-6.25
GΔDKE_CmutQ96R/K108D	T	105	1/6	1/6	5/6	100.75-4.25	100%	1/6	5/6	2/6	101.00-6.75
Georgia07/1g	M, P, U	–	–	–	–	–	0%	9/9	9/9	9/9	107.25-8.25

^aPrime and boost dose is given as TCID₅₀ and was administered intramuscularly in 1 ml PBS.

^bSigns refer to every other clinical signs observed daily besides temperatures >40.5°C.

^cPercentage of pigs that survived Georgia07/1 challenge.

^dOnly challenge virus was detected post-challenge and the titres are expressed as HAD₅₀/mL in all cases except for Group K.

^eVirus isolated from blood of Group K pigs was haemadsorbing.

^fVirus was isolated from 2 Group K pigs at low levels – one vaccine virus and the other challenge virus.

^gNon-immunized control pigs challenged at the same time as the immunized pigs.